Absci (ABSI) Operating Margin (2020 - 2026)
Absci (ABSI) posted Operating Margin of 14346.98% for Q1 2026, down 200.43% sequentially from 4775.54% in Q4 2025, and down 1199507.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Absci (ABSI) Operating Margin (2020 - 2026) Analysis & Trends
Absci has reported Operating Margin for 7 years, with the latest figure at 14346.98% in Q1 2026.
- Quarterly Operating Margin fell 1199507.0% year-over-year to 14346.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6722.98% (down 437368.0% YoY) and the FY2025 annual result came in at 4297.04%, down 189545.0% from the prior year.
- Operating Margin declined to 14346.98% in Q1 2026 per ABSI's latest filing, from 4775.54% in the prior quarter.
- Over five years, Operating Margin peaked at 1276.74% in Q2 2023 and troughed at 14346.98% in Q1 2026.
- A 5-year average of 4938.73% and a median of 4477.29% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2026: Operating Margin surged 652707 bps in 2022, then plunged 1199507 bps in 2026.
- Over 5 years, Operating Margin stood at 6222.12% in 2022, then slipped by 18 bps to 7319.23% in 2023, then jumped by 39 bps to 4477.29% in 2024, then dropped by 7 bps to 4775.54% in 2025, then sank by 200 bps to 14346.98% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 14346.98%, 4775.54%, and 7977.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | -10,741.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10,741.51% |
| Mar 31, 2026 | -14,346.98% |
| Dec 31, 2025 | -4,775.54% |
| Sep 30, 2025 | -7,977.25% |
| Jun 30, 2025 | -5,293.93% |
| Mar 31, 2025 | -2,351.91% |
| Dec 31, 2024 | -4,477.29% |
| Sep 30, 2024 | -1,698.71% |
| Jun 30, 2024 | -2,104.02% |
| Mar 31, 2024 | -2,616.70% |
| Dec 31, 2023 | -7,319.23% |
| Sep 30, 2023 | -3,132.12% |
| Jun 30, 2023 | -1,276.74% |
| Mar 31, 2023 | -1,929.47% |
| Dec 31, 2022 | -1,354.72% |
| Sep 30, 2022 | -1,180.54% |
| Jun 30, 2022 | -2,882.93% |
| Mar 31, 2022 | -3,516.85% |
| Dec 31, 2021 | -1,808.26% |
| Sep 30, 2021 | -1,373.75% |